Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Long-term follow up of patients with WHO grade 2 oligodendroglioma

Open access

Abstract

Purpose: Since the introduction of the molecular definition of oligodendrogliomas based on isocitrate dehydrogenase (IDH)-status and the 1p19q-codeletion, it has become increasingly evident how this glioma entity differs much from other diffuse lower grade gliomas and stands out with longer survival and often better responsiveness to adjuvant therapy. Therefore, apart from using a molecular oligodendroglioma definition, an extended follow-up time is necessary to understand the nature of this slow growing, yet malignant condition. The aim of this study was to describe the long-term course of the oligodendroglioma disease in a population-based setting and to determine which factors affect outcome in terms of survival. Methods: All adults with WHO-grade 2 oligodendrogliomas with known 1p19q-codeletion from five Scandinavian neurosurgical centers and with a follow-up time exceeding 5 years, were analyzed regarding survival and factors potentially affecting survival. Results: 126 patients diagnosed between 1998 and 2016 were identified. The median follow-up was 12.0 years, and the median survival was 17.8 years (95% CI 16.0–19.6). Factors associated with shorter survival in multivariable analysis were age (HR 1.05 per year; CI 1.02–1.08, p < 0.001), tumor diameter (HR 1.05 per millimeter; CI 1.02–1.08, p < 0.001) and poor preoperative functional status (KPS < 80) (HR 4.47; CI 1.70–11.78, p = 0.002). In our material, surgical strategy was not associated with survival. Conclusion: Individuals with molecularly defined oligodendrogliomas demonstrate long survival, also in a population-based setting. This is important to consider for optimal timing of therapies that may cause long-term side effects. Advanced age, large tumors and poor function before surgery are predictors of shorter survival. Graphical Abstract:

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11060-023-04368-6

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow chart depicting inclusion of 126 patients with 1p19q-codeleted oligodendroglioma
Fig. 1 Flow chart depicting inclusion of 126 patients with 1p19q-codeleted oligodendrogliomaCC BY · PubMed Central
Fig. 2 The median overall survival for all 1p19q-codeleted WHO grade 2 oligodendroglioma patients was estimated to 17.8 years (95% CI 16.0–19.6)
Fig. 2 The median overall survival for all 1p19q-codeleted WHO grade 2 oligodendroglioma patients was estimated to 17.8 years (95% CI 16.0–19.6)CC BY · PubMed Central
Fig. 3 Kaplan–Meier curves illustrating impaired survival in a older patients (p = 0.0001) and b patients with larger maximal tumor diameter (p = 0.00011)
Fig. 3 Kaplan–Meier curves illustrating impaired survival in a older patients (p = 0.0001) and b patients with larger maximal tumor diameter (p = 0.00011)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 37

Metadata

Authors
Carstam, L., Latini, F., Solheim, O., Bartek, J., Pedersen, L. K., Zetterling, M., Beniaminov, S., Sjåvik, K., Ryttlefors, M., Jensdottir, M., Rydenhag, B., Smits, A., & Jakola, A. S.
Affiliations
  • Sahlgrenska University Hospital (SE)
  • Uppsala University Hospital (SE)
  • Norwegian University of Science and Technology (NO)
  • Karolinska University Hospital (SE)
  • University Hospital of North Norway (NO)
Corresponding author
Carstam, Louise
Venue
Journal of Neuro-Oncology
Published
2023-08
Volume
164
Issue
1
Pages
65-74
ISSN
  • 0167-594X (ISSN-L)
  • 1573-7373
OpenAlex
W4386019319
Cited by
31
References
45
Citations by year
2026: 6 · 2025: 12 · 2024: 12
FWCI
5.18
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Neuro-Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, cc-by)
  • NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
Funders
  • Government and the county councils (Avtal om Läkarutbildning och Forskning (ALF)), the ALF-agreement in the form of ALF-Grant (ALFGBG-965622)
  • the Swedish Research Council (2017–00944)
  • University of Gothenburg
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
  • Health Sciences › Medicine › Clinical Neurology › Meningioma and schwannoma management
Keywords
1p/19q codeletion, long-term survival, prognostic factors, age, tumor diameter, Karnofsky performance status, surgical strategy
MeSH terms
Adult, Combined Modality Therapy, Follow-Up Studies, Glioma, Humans, Oligodendroglioma, World Health Organization

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term follow up of patients with WHO grade 2 oligodendroglioma. https://app.cochat.ai/papers/10.1007/s11060-023-04368-6
The paper
Carstam, L., Latini, F., Solheim, O., Bartek, J., Pedersen, L. K., Zetterling, M., Beniaminov, S., Sjåvik, K., Ryttlefors, M., Jensdottir, M., Rydenhag, B., Smits, A., & Jakola, A. S. (2023). Long-term follow up of patients with WHO grade 2 oligodendroglioma. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-023-04368-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.